These data show that, in several desmoplastic tumors, including pancreatic, prostate and colon cancer, ADAM12 expression stratifies patients harboring tumors with high levels of hypoxia, inflammation, tissue remodeling and innate resistance mechanisms, as well as factors associated with a poor prognosis and drug resistance such as AXL. This evidence concerns the gene ADAM12 and malignant colon neoplasm.